HEALTH CARE UTILIZATION (HCU) BY BREAST CANCER (BC) AND NON-HODGKIN LYMPHOMA (NHL) PATIENTS WITH CHEMOTHERAPY INDUCED FEBRILE NEUTROPENIA (FN) IN THE NETHERLANDS

被引：0
|
作者：
Issa, D. E. [1 ]
van Herk-Sukel, M. P. P. [2 ]
Gelderblom, H. [3 ]
Houweling, L. M. A. [2 ]
Jager, A. [4 ]
De La Orden, M. [5 ]
Lugtenburg, P. J. [4 ]
van der Werf-Langenberg, M. E. [6 ]
Nortier, J. W. R. [3 ]
de Jong, F. A. [6 ]
机构：
[1] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands
[2] PHARMO Inst, Utrecht, Netherlands
[3] Leiden Univ Med Ctr, Leiden, Netherlands
[4] Erasmus MC, Rotterdam, Netherlands
[5] Amgen Inc, Uxbridge, Middx, England
[6] Amgen BV, Breda, Netherlands
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A435 / A435
页数：1
相关论文
共 50 条
  • [31] Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy
    Lyman, GH
    Morrison, VA
    Dale, DC
    Crawford, J
    Delgado, DJ
    Fridman, M
    LEUKEMIA & LYMPHOMA, 2003, 44 (12) : 2069 - 2076
  • [32] PREDICTORS OF G-CSF PROPHYLAXIS IN THE FIRST CYCLE OF CHEMOTHERAPY FOR FEBRILE NEUTROPENIA IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA
    Lugtenburg, P.
    Asubonteng, J.
    DeCosta, L.
    Szabo, Z.
    Page, J. H.
    Wetten, S.
    HAEMATOLOGICA, 2014, 99 : 196 - 196
  • [33] ECONOMIC MODEL OF GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) IN PRIMARY (PP) AND SECONDARY PROPHYLAXIS (SP) OF FEBRILE NEUTROPENIA (FN) IN NON-HODGKIN'S LYMPHOMA (NHL) PATIENTS UNDERGOING CHEMOTHERAPY IN FRANCE
    Perrier, L.
    Sebban, C.
    Leon, N.
    Maurel, F.
    Cohen-Nizard, S.
    De Liege, F.
    VALUE IN HEALTH, 2011, 14 (07) : A450 - A450
  • [34] Breakthrough Febrile Neutropenia and Associated Complications in Non-Hodgkin's Lymphoma Patients Receiving Pegfilgrastim
    Ng, Jia Hui
    Ang, Xiu Yun
    Tan, Sze Huey
    Tao, Miriam
    Lim, Soon Thye
    Chan, Alexandre
    ACTA HAEMATOLOGICA, 2011, 125 (03) : 107 - 114
  • [35] Incidence of Febrile Neutropenia and Myelotoxicity of Chemotherapy: A Meta-Analysis of Biosimilar G-CSF Studies in Breast Cancer, Lung Cancer, and Non-Hodgkin's Lymphoma
    Engert, Andreas
    del Giglio, Auro
    Bias, Peter
    Lubenau, Heinz
    Gatzemeier, Ulrich
    Heigener, David
    ONKOLOGIE, 2009, 32 (10): : 599 - 604
  • [36] A cost-effectiveness analysis of primary prophylaxis (PP) versus secondary prophylaxis (SP) with biosimilar myeloid growth factors (MGFs) for preventing chemotherapy-induced febrile neutropenia (FN) in non-Hodgkin lymphoma (NHL) patients at intermediate risk.
    Lyman, Gary H.
    Mezzio, Dylan
    Li, Edward C.
    Campbell, Kim
    Balu, Sanjeev
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (27)
  • [37] A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma
    Intragumtornchai, T
    Sutheesophon, J
    Sutcharitchan, P
    Swasdikul, D
    LEUKEMIA & LYMPHOMA, 2000, 37 (3-4) : 351 - 360
  • [38] Population-Based Health Care Cost Estimates Related to Non-Hodgkin Lymphoma (NHL)
    Mittmann, Nicole
    Cheung, Matthew
    Isogai, Pierre K.
    Saskin, Refik
    Liu, Ning
    Hoch, Jeffrey S.
    Leighl, Natasha
    Trudeau, Maureen E.
    Evans, William K.
    Dainty, Katie N.
    Earle, Craig C.
    BLOOD, 2011, 118 (21) : 907 - 908
  • [39] Initial procalcitonin level predicts infection and its outcome in patients with non-Hodgkin lymphoma with febrile neutropenia
    Liu, Xiao
    Wang, Dao Feng
    Fang, Yi
    Ye, Wen Feng
    Liu, Shu
    Lou, Ning
    LEUKEMIA & LYMPHOMA, 2015, 56 (01) : 85 - 91
  • [40] CLINICAL CONSEQUENCES OF PRIMARY PROPHYLAXIS WITH PEGFILGRASTIM VERSUS FILGRASTIM FOR THE PREVENTION OF FEBRILE NEUTROPENIA IN NON-HODGKIN LYMPHOMA AND STAGE II BREAST CANCER PATIENTS IN GERMANY
    Ozer-Deniz, S.
    Taylor, D. C.
    Hill, G.
    Skornicki, M.
    Danel, A.
    Kunz, E.
    VALUE IN HEALTH, 2010, 13 (07) : A253 - A253
12345